NCT00979771View on ClinicalTrials.gov

A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 1, 2010

Primary Completion Date

April 28, 2011

Study Completion Date

April 28, 2011

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

GSK706769

100 mg GSK706769 twice daily orally (BID) for 28 days

DRUG

Placebo

GSK706769 matched-placebo twice daily orally (BID) for 28 days

Trial Locations (1)

1105 AZ

GSK Investigational Site, Amsterdam

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY